Starpharma Signs Second Oncology Agreement With AstraZeneca

09:00 EDT 3 Jun 2019 | Businesswire
This article has expired, however you can still download the PDF.
Starpharma has signed a Development and Option Agreement with AstraZeneca to progress the development of a Dendrimer Enhanced Product (DEP®) version of one of AstraZeneca’s major marketed oncology medicines. ...

Other Sources for this Article

WE Buchan Consulting
Rebecca Wilson
Mob: +61 417 382 391

Arthur Chan
+61 2 9237 2805

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704


More From BioPortfolio on "Starpharma Signs Second Oncology Agreement With AstraZeneca"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...